Harbin Pharmaceutical Group Co.

Harbin Pharmaceutical Group Co.

Harbin Pharmaceutical Group was founded in 1993 and listed on the Shanghai Stock Exchange that same year (ticker 600664), becoming the first publicly traded pharmaceutical company in China and the first listed company in Heilongjiang Province. The firm describes itself as a large enterprise group integrating pharmaceutical manufacturing, trade, and scientific research. The group's strategy covers drug manufacturing, trade, distribution, and R&D across a broad product portfolio. It operates through multiple subsidiaries and maintains a significant manufacturing and trading footprint primarily within China, with a focus on the domestic market. The firm's website lists categories including brand innovation, product listings, and a research platform. The firm is headquartered in Harbin, Heilongjiang, with a single known office. Through the Harbin Pharmaceutical Foundation, it engages in charitable activities such as drug donations in rural areas and support for the Harbin Marathon. The firm's 2024 and 2025 public filings provide financial performance but do not disclose AUM or third-party capital under management. A structural differentiator is its status as a state-owned enterprise that transitioned to a publicly listed corporation, governed by both stock exchange regulations and the State-owned Assets Supervision and Administration Commission (SASAC) framework. This hybrid governance model shapes its capital allocation and strategic priorities, distinct from purely private or purely state-owned pharmaceutical groups.